A Meta-analysis of Genotypes and Haplotypes of Methylenetetrahydrofolate Reductase Gene Polymorphisms in Breast Cancer

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2014 Jun 30

PMID 24973876

Citations 7

Authors

Shanliang Zhong

Zhiyuan Chen

Xinnian Yu

Wenjing Li

Jinhai Tang

Jianhua Zhao

Affiliations

Soon will be listed here.

Abstract

The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk has been extensively explored, but their results are conflicting rather than conclusive. To derive a more precise estimation, we carried out not only an updated meta-analysis but also a combined analysis based on all the available studies estimating the association between MTHFR C677T and/or A1298C and breast cancer risk. With respect to C677T polymorphism, the results suggested that 677T allele was associated with significantly elevated breast cancer risk in overall analysis (T vs. C: OR 1.073, 95 % CI 1.028-1.120; TT vs. CC: OR 1.177, 95 % CI 1.072-1.293; TT vs. CC + CT: OR 1.175, 95 % CI 1.073-1.288); Stratifying by ethnicity, significantly increased risk was only found in East Asians (T vs. C: OR 1.150, 95 % CI 1.039-1.273; TT vs. CC: OR 1.441, 95 % CI 1.145-1.814; TT vs. CC + CT: OR 1.413, 95 % CI 1.148-1.739); When stratified by menopausal status, statistically significant association was found for postmenopausal women (CT + TT vs. CC: OR 1.092, 95 % CI 1.011-1.179). In regard to A1298C polymorphism, no significant associations were found between the polymorphism and breast cancer risk. With respect to MTHFR haplotypes, significantly elevated breast cancer risk was associated with 677T-1298C for overall result (OR 1.498, 95 % CI 1.143-1.962) and for Caucasians (OR 2.088, 95 % CI 1.277-3.416) when compared with 677C-1298A; Haplotype 677C-1298C might provide higher protection than 677C-1298A in East Asians (OR 0.840, 95 % CI 0.742-0.949). The combined genotypes for C677T and A1298C produced a significant OR for the 677TT/1298AC relative to 677CC/1298AA in overall population (OR 2.047, 95 % CI 1.275-3.288); When stratified by ethnicity, significant ORs were only found for East Asians (677CC/1298CC vs. 677CC/1298AA: OR 0.686, 95 % CI 0.478-0.985; 677TT/1298AC vs. 677CC/1298AA: OR 2.181, 95 % CI 1.179-4.035). The findings suggest that the MTHFR C677T polymorphism but not A1298C, and some variants on their combined genotypes or haplotypes may be involved with the development of breast cancer.

Citing Articles

Strong Correlation of MTHFR Gene Polymorphisms with Breast Cancer and its Prognostic Clinical Factors among Egyptian Females.

Omran M, Fotouh B, Shousha W, Ismail A, Ibrahim N, Ramadan S Asian Pac J Cancer Prev. 2021; 22(2):617-626.

PMID: 33639682 PMC: 8190368. DOI: 10.31557/APJCP.2021.22.2.617.

MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: a case-control study in a population from North Sardinia.

Floris M, Sanna D, Castiglia P, Putzu C, Sanna V, Pazzola A BMC Cancer. 2020; 20(1):234.

PMID: 32192442 PMC: 7083022. DOI: 10.1186/s12885-020-06749-w.

Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.

Hardi H, Melki R, Boughaleb Z, El Harroudi T, Aissaoui S, Boukhatem N BMC Cancer. 2018; 18(1):292.

PMID: 29544444 PMC: 5856390. DOI: 10.1186/s12885-018-4214-z.

MTHFR Gene Polymorphism-Mutations and Air Pollution as Risk Factors for Breast Cancer: A Metaprediction Study.

Gonzales M, Yu P, Shiao S Nurs Res. 2017; 66(2):152-163.

PMID: 28114181 PMC: 5345887. DOI: 10.1097/NNR.0000000000000206.

Combined genotype and haplotype distributions of MTHFR C677T and A1298C polymorphisms: A cross-sectional descriptive study of 13,473 Chinese adult women.

Fan S, Yang B, Zhi X, Wang Y, Zheng Q, Sun G Medicine (Baltimore). 2016; 95(48):e5355.

PMID: 27902594 PMC: 5134799. DOI: 10.1097/MD.0000000000005355.

References

Kim Y . Folate and cancer prevention: a new medical application of folate beyond hyperhomocysteinemia and neural tube defects. Nutr Rev. 1999; 57(10):314-21. DOI: 10.1111/j.1753-4887.1999.tb06905.x. View

Jin Z, Lu Q, Ge D, Zong M, Zhu Q . Effect of the methylenetetrahydrofolate reductase gene C677T polymorphism on C-erbB-2 methylation status and its association with cancer. Mol Med Rep. 2011; 2(2):283-9. DOI: 10.3892/mmr_00000097. View

Maruti S, Ulrich C, Jupe E, White E . MTHFR C677T and postmenopausal breast cancer risk by intakes of one-carbon metabolism nutrients: a nested case-control study. Breast Cancer Res. 2009; 11(6):R91. PMC: 2815555. DOI: 10.1186/bcr2462. View

Gao C, Kazuo T, Tang J, Cao H, Ding J, Wu J . [MTHFR polymorphisms, dietary folate intake and risks to breast cancer]. Zhonghua Yu Fang Yi Xue Za Zhi. 2009; 43(7):576-80. View

Kalemi T, Lambropoulos A, Gueorguiev M, Chrisafi S, T Papazisis K, Kotsis A . The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett. 2005; 222(1):57-65. DOI: 10.1016/j.canlet.2004.11.025. View

Shaik Mohammad N, Yedluri R, Addepalli P, Gottumukkala S, Digumarti R, Kutala V . Aberrations in one-carbon metabolism induce oxidative DNA damage in sporadic breast cancer. Mol Cell Biochem. 2010; 349(1-2):159-67. DOI: 10.1007/s11010-010-0670-8. View

Henriquez-Hernandez L, Murias-Rosales A, Hernandez Gonzalez A, Cabrera de Leon A, Diaz-Chico B, Mori De Santiago M . Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study. Oncol Rep. 2009; 22(6):1425-33. DOI: 10.3892/or_00000584. View

Stephens M, Donnelly P . A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003; 73(5):1162-9. PMC: 1180495. DOI: 10.1086/379378. View

Lissowska J, Gaudet M, Brinton L, Chanock S, Peplonska B, Welch R . Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: a population-based case-control study and meta-analyses. Int J Cancer. 2007; 120(12):2696-703. DOI: 10.1002/ijc.22604. View

10.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

11.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

12.

Zintzaras E . Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a meta-analysis. Clin Genet. 2006; 69(4):327-36. DOI: 10.1111/j.1399-0004.2006.00605.x. View

13.

Zintzaras E, Koufakis T, Ziakas P, Rodopoulou P, Giannouli S, Voulgarelis M . A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia. Eur J Epidemiol. 2006; 21(7):501-10. DOI: 10.1007/s10654-006-9027-8. View

14.

Qi X, Ma X, Yang X, Fan L, Zhang Y, Zhang F . Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls. Breast Cancer Res Treat. 2010; 123(2):499-506. DOI: 10.1007/s10549-010-0773-7. View

15.

Reljic A, Simundic A, Topic E, Nikolac N, Justinic D, Stefanovic M . The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and cancer risk: the Croatian case-control study. Clin Biochem. 2007; 40(13-14):981-5. DOI: 10.1016/j.clinbiochem.2007.05.005. View

16.

Naushad S, Pavani A, Digumarti R, Gottumukkala S, Kutala V . Epistatic interactions between loci of one-carbon metabolism modulate susceptibility to breast cancer. Mol Biol Rep. 2010; 38(8):4893-901. DOI: 10.1007/s11033-010-0631-z. View

17.

Prasad V, Wilkhoo H . Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie. 2011; 34(8-9):422-6. DOI: 10.1159/000331131. View

18.

Bentley A, Raiszadeh F, Stover P, Hunter D, Hankinson S, Cassano P . No association between cSHMT genotypes and the risk of breast cancer in the Nurses' Health Study. Eur J Clin Nutr. 2009; 64(1):108-10. PMC: 3033771. DOI: 10.1038/ejcn.2009.104. View

19.

Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z . A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009; 19(4):519-23. DOI: 10.1038/cr.2009.33. View

20.

Jakubowska A, Jaworska K, Cybulski C, Janicka A, Szymanska-Pasternak J, Lener M . Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers?. Eur J Cancer. 2008; 45(5):837-42. DOI: 10.1016/j.ejca.2008.10.021. View